Pembrolizumab
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical, Vaginal and Vulval Inflammatory Diseases
Conditions
Cervical, Vaginal and Vulval Inflammatory Diseases
Trial Timeline
Oct 14, 2020 → Sep 1, 2024
NCT ID
NCT04211103About Pembrolizumab
Pembrolizumab is a phase 2 stage product being developed by Merck for Cervical, Vaginal and Vulval Inflammatory Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT04211103. Target conditions include Cervical, Vaginal and Vulval Inflammatory Diseases.
What happened to similar drugs?
8 of 20 similar drugs in Cervical, Vaginal and Vulval Inflammatory Diseases were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083484 | Pre-clinical | Completed |
| NCT07302347 | Phase 1/2 | Recruiting |
| NCT07089992 | Phase 2 | Recruiting |
| NCT07007273 | Phase 2 | Recruiting |
| NCT04569461 | Phase 2 | Withdrawn |
| NCT05815927 | Phase 3 | Recruiting |
| NCT05852223 | Phase 2 | Recruiting |
| NCT05879120 | Phase 2 | Withdrawn |
| NCT06004336 | Phase 2 | Recruiting |
| NCT05496036 | Phase 2 | Recruiting |
| NCT05131919 | Phase 2 | Active |
| NCT05197322 | Phase 2 | Recruiting |
| NCT05406713 | Phase 2 | Active |
| NCT05025813 | Phase 2 | Recruiting |
| NCT06413095 | Phase 1 | Completed |
| NCT05191472 | Phase 2 | Terminated |
| NCT05204160 | Phase 2 | Withdrawn |
| NCT04575961 | Phase 2 | Active |
| NCT04417166 | Phase 2 | Recruiting |
| NCT05188508 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cervical, Vaginal and Vulval Inflammatory Diseases